News
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Aurinia Announces Board Restructuring
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has restructured its Board of Directors (the Board) to further align the Company with shareholder
ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology
Xencor Announces Proposed Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it
Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being
Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being
EQS-News: Abivax presents first-half 2024 financial results
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine
Agilent Technologies Inc., (NYSE: A) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM)
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb®
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On September 5
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will
Inogen Appoints Eric Pauls as Vice President of Sales, North America
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a
Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at
Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of the
ICON plc to Present at the Baird 2024 Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global